Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Advax-CpG55.2
- Development stage
- Unknown
- Lead developer
- Vaxine
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Advax-CpG55.2 is a combination adjuvant system developed by Vaxine Pty Ltd and evaluated by the National Institute of Allergy and Infectious Diseases (NIAID). It is composed of two active components: delta inulin (Advax), a plant-derived polysaccharide particle that targets DC-SIGN on dendritic cells, and CpG55.2, a synthetic B-class oligonucleotide with a phosphorothioate backbone that acts as a Toll-like receptor 9 (TLR9) agonist. This adjuvant is designed to enhance both humoral and cellular immune responses when formulated with vaccines. It has been primarily evaluated in Phase I clinical trials (NCT03945825) in combination with quadrivalent seasonal influenza vaccines, such as Fluzone (inactivated) and Flublok (recombinant), to improve antibody titers and neutralizing responses in healthy adults.
- Brand names
- Advax
- Other names
- Delta Inulin + CpG55.2
02
Targets
TLR9 (Toll-like receptor 9)CD209 (Dendritic cell-specific intercellular adhesion Molecule-3-Grabbing non-integrin)
Beyond the preview
Go deeper on Advax-CpG55.2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Advax-CpG55.2.